MedPath

Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China

Completed
Conditions
Rectal Cancer
Registration Number
NCT05108753
Lead Sponsor
Shanghai Minimally Invasive Surgery Center
Brief Summary

Transanal total mesorectal excision (TaTME) is an alternative for mid-low rectal cancer. In China, this procedure has been performed in high-volume centers with structured training curriculums. This study aimed to evaluate the short-term outcomes during the initial implementation of the TaTME procedure in high-volume centers who followed structured training curriculums in China.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
175
Inclusion Criteria
  • Age between 18 and 75 years
  • American Society of Anesthesiologists (ASA) score I to III
  • A biopsy proven histological diagnosis of rectal carcinoma
  • Undergoing transanal total mesorectal excision
Exclusion Criteria
  • Pregnant or lactating women
  • Synchronous rectal carcinoma
  • History of colorectal cancer or other malignant tumors
  • Clinical evidence of metastasis
  • Emergency procedure

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
incidence of anastomotic leakagethirty days after surgery

according to the International Rectal Cancer Study Group

Secondary Outcome Measures
NameTimeMethod
incidence of positivecircumferential resection margin30 days after surgery

The positive circumferential resection margin (CRM) was defined as the presence of tumor cells within 1 mm from the CRM

incidence of Defecation disorders6 months after surgery

A Wexner score \>10 indicated the existence of defecation dysfunction

incidence of positive distal resection margin30 days after surgery

A positive distal resection margin (DRM) was diagnosed with the presence of tumor cells within 1mm from the DRM

Trial Locations

Locations (2)

Ruijin Hospital

🇨🇳

Shanghai, Shanghai, China

Shanghai Minimally Invasive Surgery Center

🇨🇳

Shanghai, China

Ruijin Hospital
🇨🇳Shanghai, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.